



## Claims:

1. A substituted 4-, 5-, 6-, or 7-indole or indoline derivative of Formula



wherein W is N, C, CH or COH and the dotted lines indicate optional bonds and

wherein A is a group having the formula



wherein X is CR<sup>1A</sup>, CHR<sup>1A</sup>, N, NR<sup>1B</sup>, O, or S, where R<sup>1A</sup> is as defined for R<sup>3</sup> to R<sup>9</sup> below, and where R<sup>1B</sup> is as defined for R<sup>10</sup> below;


Y is CR<sup>2A</sup>, CHR<sup>2A</sup>, N, NR<sup>2B</sup>, O, or S, where R<sup>2A</sup> is as defined for R<sup>3</sup> to R<sup>9</sup> below and where R<sup>2B</sup> is as defined for R<sup>10</sup> below, and

the dotted lines indicate optional bonds;

provided that X and Y are not both O or S;

48

A is a group having the formula




5 wherein X is  $CR^{1A}$ ,  $CHR^{1A}$ , N,  $NR^{1B}$ , O, or S, where  $R^{1A}$  is as defined for  $R^3$  to  $R^9$  below, and where  $R^{1B}$  is as defined for  $R^{10}$  below;

U is C, CH, or N; and

10 the dotted lines indicate optional bonds; or

A is a group having the formula



15 wherein U is C, CH, or N;

Y is  $CR^{2A}$ ,  $CHR^{2A}$ , N,  $NR^{2B}$ , O, or S, where  $R^{2A}$  is as defined for  $R^3$  to  $R^9$  below and where  $R^{2B}$  is as defined for  $R^{10}$  below; and

20 the dotted lines indicate optional bonds;

n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5;

Z is CH<sub>2</sub>, O, S, CO, SO, or SO<sub>2</sub>, provided that if n is 0 then Z is CH<sub>2</sub>;

- R<sup>3</sup>-R<sup>9</sup> and R<sup>11</sup> to R<sup>12</sup> are independently selected from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, hydroxy-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxycarbonyl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, C<sub>1-6</sub> alkylsulfonyl, aryl and heteroaryl, and/or two adjacent groups taken from R<sup>3</sup> - R<sup>9</sup> may together form a methylenedioxy group,
- and/or two adjacent groups R<sup>7</sup> - R<sup>9</sup> may together form a cyclopentyl or cyclohexyl ring which may be substituted with one or more methyl groups, and/or one of R<sup>3</sup>-R<sup>9</sup> may alternatively be a group -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> is as defined for R<sup>10</sup> below and R<sup>14</sup> is hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub> alk(en/yn)yl, aryl, heteroaryl, aryl-C<sub>1-6</sub> alkyl, or heteroaryl-C<sub>1-6</sub> alkyl;


R<sup>10</sup> is

- hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl, heteroaryl, aryl-C<sub>1-6</sub>-alkyl, heteroaryl-C<sub>1-6</sub>-alkyl, acyl, thioacyl, C<sub>1-6</sub>-alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, or heteroarylsulfonyl;
- R<sup>15</sup>VCO- wherein V is O or S and R<sup>15</sup> is C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl, or heteroaryl; or
- a group R<sup>16</sup>R<sup>17</sup>NCO- or R<sup>16</sup>R<sup>17</sup>NCS- wherein R<sup>16</sup> and R<sup>17</sup> are independently selected from hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, heteroaryl, or aryl, or R<sup>16</sup> and R<sup>17</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, morpholinyl, or perhydroazepin group;

or an acid addition salt thereof.

2. A compound according to claim 1 wherein A is a group having the formula


50



wherein X, Y, the dotted lines and  $R^3$  -  $R^6$  are as defined in claim 1.

5

3. A compound according to claim 2 wherein A is a group having the formula




10

wherein  $R^3$  to  $R^6$  and the dotted lines are as defined in claim 2.

51

4. A compound according to claim 3 wherein A is a group having the formula




5

wherein  $R^3$  to  $R^6$  and the dotted lines are as defined in claim 3.

5. A compound according to claim 1 having the formula

10



wherein  $R^7$  to  $R^{12}$ , W, A, Z, n, m and the dotted lines are as defined in claim 1.


15

6. A compound according to claims 1 to 5 wherein Z is  $CH_2$  and  $n + m$  is 0, 1, 2, 3, 4, 5, or 6.


Sub  
AS

7. A compound according to claim 1-6 wherein W is N.

8. A compound according to claim 1 having the formula




wherein  $R^7$  to  $R^{12}$ , W, Z, n, m and the dotted lines are as defined in claim 1 and A is a group having the formula



wherein X, Y, the dotted lines and  $R^3$ - $R^6$  is as defined in claim 1.


9. A compound according to claim 8 wherein A is a group having the formula



wherein  $R^3$  to  $R^6$  and the dotted line is as defined in claim 8.

5

10. A compound according to claim 9 wherein A is a group having the formula



wherein  $R^3$  to  $R^6$  and the dotted line is as defined in claim 9.

5

11. A compound of claims 1-10 wherein Z is  $CH_2$  and  $n + m$  is 0, 1, 2, 3, 4, 5, or 6 and  $R^3$ - $R^9$  and  $R^{11}$ - $R^{12}$  is hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, hydroxy, hydroxy- $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxycarbonyl and trifluoromethyl; and  $R^{10}$  is hydrogen.

10

12. A compound according to claim 8 -11 wherein W is N.

13. A compound according to claim 1 which is

1-(2-(3-Benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

15 1-(3-Benzofuranylmethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(5-Fluoro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(4-(5-Fluoro-3-benzofuranyl)-1-butyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(1H-Indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(3-(1H-Indol-3-yl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

20 1-(4-(1H-Indol-3-yl)-1-butyl)-4-(1H-indol-4-yl)piperazine,

1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

- Sub A7
- 1-(2-(2-Methyl-4,5,6,7-tetrafluoro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(3-Indazolyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-3-indazolyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(7-Cyano-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
5 1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,  
1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,  
10 1-(2-(7-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(1-Allyl-1H-indol-4-yl)-4-(2-(6-chloro-1H-indol-3-yl)ethyl)piperazine,  
1-(1-Allyl-1H-indol-4-yl)-4-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperazine,  
1-(1-Benzyl-1H-indol-4-yl)-4-(2-(6-chloro-1H-indol-3-yl)ethyl)piperazine,  
1-(1-Benzyl-1H-indol-4-yl)-4-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperazine,  
15 1-(1-Benzyl-1H-indol-4-yl)-4-(2-(5-bromo-1H-indol-3-yl)ethyl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,  
1-(2-(1H-Indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,  
1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,  
1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,  
20 1-(1-Benzyl-1H-indol-4-yl)-4-(2-(1H-indol-3-yl)ethyl)piperazine,  
1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-5-yl)piperazine,  
1-(2-(5-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-5-yl)piperazine,  
1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,  
25 1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,  
1-(3-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-propyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(1H-Indol-3-yl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-yl)piperazine,  
1-(2-(5-Fluoro-3-benzofuranyl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-  
30 yl)piperazine,  
1-(5-Fluoro-3-benzofuranylmethyl)-4-(1H-indol-4-yl)piperazine,  
1-(3-Cyano-1H-indol-4-yl)-4-(2-(1H-indol-3-yl)ethyl)piperazine,

1-(3-Cyano-1H-indol-4-yl)-4-(2-(5-fluoro-3-benzofuranyl)ethyl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,  
1-(2-(3-Benzofuranyl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(5-methyl-3-benzofuranyl)ethyl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(4-methyl-3-benzofuranyl)ethyl)piperazine,  
1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,  
1-(2-(5-Chloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(6-methyl-3-benzofuranyl)ethyl)piperazine,  
1-(2-(7-Chloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)-4-(1H-indol-4-yl)piperidine,  
1-(2-(5-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(7-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(6-Trifluoromethyl-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(5-methyl-1H-indol-3-yl)ethyl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(6-methyl-1H-indol-3-yl)ethyl)piperazine,  
1-(1H-Indol-4-yl)-4-(2-(7-methyl-1H-indol-3-yl)ethyl)piperazine,  
1-(2-(4,5-Dichloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(5-Bromo-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperidine,  
4-(1H-Indol-4-yl)-1-(2-(5-methyl-1H-indol-3-yl)ethyl)piperidine,  
4-(1H-Indol-4-yl)-1-(2-(1H-indol-3-yl)ethyl)piperidine,  
1-(1H-Indol-4-yl)-4-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperazine,  
4-(1H-Indol-4-yl)-1-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperidine,  
1-(3-(4-Chloro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-chloro-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-fluoro-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-cyano-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(7-chloro-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(7-cyano-1H-indol-4-yl)piperazine.

Sub A7  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(2-cyano-1H-indol-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indolin-4-yl)piperazine,  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-6-yl)piperazine and  
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-7-yl)piperazine or a  
5 pharmaceutically acceptable acid addition salt thereof.

14. A pharmaceutical composition comprising a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

10  
15. The use of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of a disorder or disease responsive to the inhibition of serotonin reuptake and antagonism of 5-HT<sub>1A</sub> receptors.

15  
16. The use of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of affective disorders, such as depression, psychosis, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive  
20 disorder.

17. A method for the treatment of a disorder or disease of living animal body, including a human, which is responsive to the inhibition of serotonin reuptake and antagonism of 5-HT<sub>1A</sub> receptors comprising administering to such a living animal  
25 body, including a human, a therapeutically effective amount of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof.

18. A method for the treatment of an affective disorder, including depression psychosis, anxiety disorders including general anxiety disorder and panic disorder and  
30 obsessive compulsive disorder in a living animal body, including a human, comprising administering a therapeutically effective amount of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof.